GSK (GSK) RNS Announcements

Add to Alert list
Date Time Source Announcement
02 Dec 2015 04:38 PM
RNS
Nucala European Marketing Authorisation Received
01 Dec 2015 03:21 PM
RNS
Director/PDMR Shareholding
01 Dec 2015 01:09 PM
RNS
Total Voting Rights
13 Nov 2015 02:14 PM
RNS
Director/PDMR Shareholding
12 Nov 2015 03:41 PM
RNS
Blocklisting Interim Review
11 Nov 2015 03:10 PM
RNS
Director/PDMR Shareholding
05 Nov 2015 07:00 AM
RNS
GSK's Nucala® receives approval from US FDA
03 Nov 2015 11:56 AM
RNS
ViiV Healthcare announces positive results
03 Nov 2015 11:56 AM
RNS
GSK profiles innovative R&D portfolio to investors
02 Nov 2015 12:45 PM
RNS
Director Declaration
02 Nov 2015 10:31 AM
RNS
Total Voting Rights
29 Oct 2015 03:39 PM
RNS
Director/PDMR Shareholding
28 Oct 2015 12:00 PM
RNS
3rd Quarter Results
27 Oct 2015 10:50 AM
RNS
Results of LABA safety study for Advair Diskus
27 Oct 2015 10:50 AM
RNS
90% efficacy in shingles vaccine for over 70's
20 Oct 2015 04:57 PM
RNS
Director/PDMR Shareholding
20 Oct 2015 04:52 PM
RNS
Director/PDMR Shareholding
20 Oct 2015 01:20 PM
RNS
Director/PDMR Shareholding
20 Oct 2015 01:14 PM
RNS
Director/PDMR Shareholding
20 Oct 2015 01:02 PM
RNS
Positive Data for Incruse Ellipta Comparisons
19 Oct 2015 02:38 PM
RNS
Director/PDMR Shareholding
19 Oct 2015 02:36 PM
RNS
Director/PDMR Shareholding
19 Oct 2015 02:34 PM
RNS
Director/PDMR Shareholding
13 Oct 2015 01:54 PM
RNS
Director/PDMR Shareholding
12 Oct 2015 04:52 PM
RNS
Director/PDMR Shareholding
08 Oct 2015 12:29 PM
RNS
Director/PDMR Shareholding
07 Oct 2015 12:26 PM
RNS
Director/PDMR Shareholding
05 Oct 2015 10:00 AM
RNS
Director/PDMR Shareholding
02 Oct 2015 02:35 PM
RNS
Director/PDMR Shareholding
02 Oct 2015 02:32 PM
RNS
Director/PDMR Shareholding
01 Oct 2015 12:07 PM
RNS
Director/PDMR Shareholding
01 Oct 2015 09:58 AM
RNS
Total Voting Rights
30 Sep 2015 01:40 PM
RNS
Director/PDMR Shareholding
28 Sep 2015 04:54 PM
RNS
Director/PDMR Shareholding
24 Sep 2015 02:54 PM
RNS
CHMP opinion for mepolizumab (Nucala) in Europe
24 Sep 2015 08:03 AM
RNS
Intention to file Relvar Ellipta for COPD in Japan
23 Sep 2015 08:30 AM
RNS
ViiV Healthcare Phase lllb/IV STRIIVING data
17 Sep 2015 12:13 PM
RNS
Director/PDMR Shareholding
14 Sep 2015 03:52 PM
RNS
Director/PDMR Shareholding
10 Sep 2015 01:06 PM
RNS
Director/PDMR Shareholding
09 Sep 2015 07:00 AM
RNS
Results from the SUMMIT COPD CV Survival Study
01 Sep 2015 09:47 AM
RNS
Total Voting Rights
01 Sep 2015 09:43 AM
RNS
Director/PDMR Shareholding
01 Sep 2015 09:41 AM
RNS
Director/PDMR Shareholding
28 Aug 2015 03:14 PM
RNS
Director/PDMR Shareholding
27 Aug 2015 12:31 PM
RNS
Director/PDMR Shareholding
21 Aug 2015 07:00 AM
RNS
GSK to divest ofatumumab - auto-immune indications
14 Aug 2015 04:49 PM
RNS
Director/PDMR Shareholding
12 Aug 2015 03:32 PM
RNS
Director/PDMR Shareholding
05 Aug 2015 03:41 PM
RNS
Director/PDMR Shareholding

GSK PLC, known as GSK, is a renowned multinational pharmaceutical and biotechnology company with its global headquarters in London. Traded as GSK on the London Stock Exchange (LSE), it has a rich history that traces back to the establishment of Plough Court Pharmacy in London in 1715. Over the centuries, GSK has grown from a handful of individual founders into a company of over 69,000 people.

The company's journey includes the development of 15 first-in-class or combination vaccines and pioneering medications in respiratory, antibiotics, antivirals, and oncology. GSK has been a leader in medicines that advance the management of asthma and chronic obstructive pulmonary disease (COPD) for 50 years.

In 2000, Glaxo Wellcome and SmithKline Beecham merged to form the modern GSK, becoming a key player on the LSEG. Today, GSK continues to shape the global healthcare landscape, committed to defeating diseases that impact people's health. This evergreen company remains at the forefront of the pharmaceutical industry, embodying its founding principle of improving the quality of human life by enabling people to do more, feel better, and live longer.

GSK share price launched at 346p in 1989. 

UK 100

Latest directors dealings